Research on cloud manufacturing platform for small and medium-sized enterprises

With the adjustment of China’s economic structure, it is essential for manufacturing enterprises, especially SMEs, to improve their core competitiveness. Based on the service mode of Cloud manufacturing, this paper designs and develops a cloud manufacturing platform for SMEs. Firstly, according to the characteristics of cloud manufacturing, the overall framework of the platform is determined, and the corresponding function tree is refined. Then, the key technologies are studied, including the modeling and standardization of manufacturing services, the matching of task, the execution, the online monitoring of service, and the evaluation of post-service. The functions of service access, service matching, outsourcing task management, remote monitoring, and evaluation of tasks are realized. Finally, the platform is applied in the mold manufacturing industry, and an example analysis is carried out to verify the effectiveness of the proposed platform

Research on cloud manufacturing platform for small and medium-sized enterprises

With the adjustment of China’s economic structure, it is essential for manufacturing enterprises, especially SMEs, to improve their core competitiveness. Based on the service mode of Cloud manufacturing, this paper designs and develops a cloud manufacturing platform for SMEs. Firstly, according to the characteristics of cloud manufacturing, the overall framework of the platform is determined, and the corresponding function tree is refined. Then, the key technologies are studied, including the modeling and standardization of manufacturing services, the matching of task, the execution, the online monitoring of service, and the evaluation of post-service. The functions of service access, service matching, outsourcing task management, remote monitoring, and evaluation of tasks are realized. Finally, the platform is applied in the mold manufacturing industry, and an example analysis is carried out to verify the effectiveness of the proposed platform

DRIFTS-MS Investigation of Low-Temperature CO Oxidation on Cu-Doped Manganese Oxide Prepared Using Nitrate Aerosol Decomposition

Cu-doped manganese oxide (Cu–Mn2O4) prepared using aerosol decomposition was used as a CO oxidation catalyst. Cu was successfully doped into Mn2O4 due to their nitrate precursors having closed thermal decomposition properties, which ensured the atomic ratio of Cu/(Cu + Mn) in Cu–Mn2O4 close to that in their nitrate precursors. The 0.5Cu–Mn2O4 catalyst of 0.48 Cu/(Cu + Mn) atomic ratio had the best CO oxidation performance, with T50 and T90 as low as 48 and 69 °C, respectively. The 0.5Cu–Mn2O4 catalyst also had (1) a hollow sphere morphology, where the sphere wall was composed of a large number of nanospheres (about 10 nm), (2) the largest specific surface area and defects on the interfacing of the nanospheres, and (3) the highest Mn3+, Cu+, and Oads ratios, which facilitated oxygen vacancy formation, CO adsorption, and CO oxidation, respectively, yielding a synergetic effect on CO oxidation. DRIFTS-MS analysis results showed that terminal-type oxygen (M=O) and bridge-type oxygen (M-O-M) on 0.5Cu–Mn2O4 were reactive at a low temperature, resulting in-good low-temperature CO oxidation performance. Water could adsorb on 0.5Cu–Mn2O4 and inhibited M=O and M-O-M reaction with CO. Water could not inhibit O2 decomposition to M=O and M-O-M. The 0.5Cu–Mn2O4 catalyst had excellent water resistance at 150 °C, at which the influence of water (up to 5%) on CO oxidation could be completely eliminated

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

Cancer League of Colorado [BCTR0707449, AWD-102888]; Colorado CTSA grant [UL1TR000154]; NCATS/NIH; National Natural Science Foundation of China [81272922]Introduction: Elevated expression of erbB3 rendered erbB2-overexpressing breast cancer cells resistant to paclitaxel via PI-3 K/Akt-dependent upregulation of Survivin. It is unclear whether an erbB3-targeted therapy may abrogate erbB2-mediated paclitaxel resistance in breast cancer. Here, we study the antitumor activity of an anti-erbB3 antibody MM-121/SAR256212 in combination with paclitaxel against erbB2-overexpressing breast cancer. Methods: Cell growth assays were used to determine cell viability. Cells undergoing apoptosis were quantified by a specific apoptotic ELISA. Western blot analyses were performed to assess the protein expression and activation. Lentiviral vector containing shRNA was used to specifically knockdown Survivin. Tumor xenografts were established by inoculation of BT474-HR20 cells into nude mice. The tumor-bearing mice were treated with paclitaxel and/or MM-121/SAR256212 to determine whether the antibody (Ab) enhances paclitaxel's antitumor activity. Immunohistochemistry was carried out to study the combinatorial effects on tumor cell proliferation and induction of apoptosis in vivo. Results: MM-121 significantly facilitated paclitaxel-mediated anti-proliferative/anti-survival effects on SKBR3 cells transfected with a control vector or erbB3 cDNA. It specifically downregulated Survivin associated with inactivation of erbB2, erbB3, and Akt. MM-121 enhances paclitaxel-induced poly(ADP-ribose) polymerase (PARP) cleavage, activation of caspase-8 and -3, and apoptosis in both paclitaxel-sensitive and -resistant cells. Specific knockdown of Survivin in the trastuzumab-resistant BT474-HR20 cells dramatically enhanced paclitaxel-induced apoptosis, suggesting that increased Survivin caused a cross-resistance to paclitaxel. Furthermore, the studies using a tumor xenograft model-established from BT474-HR20 cells revealed that either MM-121 (10 mg/kg) or low-dose (7.5 mg/kg) paclitaxel had no effect on tumor growth, their combinations significantly inhibited tumor growth in vivo. Immunohistochemical analysis showed that the combinations of MM-121 and paclitaxel significantly reduced the cells with positive staining for Ki-67 and Survivin, and increased the cells with cleaved caspase-3. Conclusions: The combinations of MM-121 and paclitaxel not only inhibit tumor cell proliferation, but also promote erbB2-overexpressing breast cancer cells to undergo apoptosis via downregulation of Survivin in vitro and in vivo, suggesting that inactivation of erbB3 with MM-121 enhances paclitaxel-mediated antitumor activity against erbB2overexpressing breast cancers. Our data supports further exploration of the combinatorial regimens consisting of MM-121 and paclitaxel in breast cancer patients with erbB2-overexpressing tumors, particularly those resistant to paclitaxel